Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
CEO Brett Monia Took The Helm At Start Of Transition
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.
You may also be interested in...
Giving up on adding a cardiomyopathy indication to Onpattro’s label, Alnylam now will focus on adding that disease to Amvuttra’s label. Onpattro got a thumbs-up from an FDA advisory panel in September.
Public Company Edition: Follow-on offerings did not surge after ASCO, but Day One and Cogent raised $150m-plus. Also, IQVIA and Ionis sold $1.25bn and $500m in notes, while Krystal and Lexicon grossed $160m and $125m from post-approval offerings.
Patients continued to improve across all three Phase III NEURO-TTRansform co-primary endpoints with 29 more weeks of treatment, setting up eplontersen to challenge Alnylam’s Amvuttra.